Our findings highlight that ANO1 is an actionable target in HNSCC, as well as that novel ANO1-small molecule inhibitor, Ani9-5f, and BH3-mimetic, AZD-5991, are compounds with high clinical relevance for a subset of HPV-negative HNSCCs. Here, ANO1 is linked to head and neck squamous cell carcinoma.